Generics competition for Pfizer’s sildenafil

Generics and biosimilars Initiative

Building trust in cost-effective treatments

Inscribirse
eng / esp

Generics competition for Pfizer’s sildenafil

Genéricos/Novedades | Posted 23/11/2012 0 Post your comment

Apotex Corporation, Dr Reddy’s Laboratories, Mylan, Torrent Pharmaceuticals and Watson Laboratories have all received FDA approval for bioequivalent generic versions of Pfizer’s Revatio (sildenafil citrate – Viagra in Europe) in the US market following the approval by FDA of the generics companies abbreviated new drug applications (ANDAs) for sildenafil tablets.

The erectile dysfunction drug has been a big earner for Pfizer. The Revatio brand had US sales of approximately US$339 million for the twelve months ending September 2012 according to IMS Health.

Pfizer had tried to stop generic versions hitting the market in the US by filing a patent-infringement lawsuit against generics companies Actavis, Amneal Pharmaceuticals, Apotex and Mylan, all of whom had submitted ANDAs for sildenafil citrate to FDA. Pfizer had thought that its 2012 patent would protect the blockbuster until it expired in October 2019, however, it seems the pharma giant has lost its fight.

Viagra is the world leader in erectile dysfunction, and Pfizer has much to lose. Worldwide sales in 2009 of US$1.89 billion made up approximately 3.8% of Pfizer’s total revenue.

Permission granted to reproduce for personal and educational use only. All other reproduction, copy, retransmission or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Source: Dr Reddy’s, FDA, Watson